45 results about "Sacroiliitis" patented technology

The invention discloses a novel benzofuran component in eupatorium chinense and application of the benzofuran component in anti-inflammatory activity. The obtained compound is separated from an eupatorium chinense extract. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, Sephadex LH-20 gel column chromatography, high performance liquid chromatography and other methods. According to the present invention, all the separated compounds and the analogues thereof have good inhibition activity on target cyclooxygenase-2 of inflammation-related diseases, and have good inhibition activity on COX-2 enzyme, and the molecular docking experiment results show that the compounds and the target proteins have good binding energy. Therefore, the compound can be used for preparing drugs for treating inflammatory related diseases, or anti-inflammatory and analgesic drugs, or tumor drugs by inhibiting COX-2 enzyme, such as drugs for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, Alzheimer's disease and the like, and related natural lead compounds are provided.

A sacroiliac (SI) joint implant assembly addresses SI joint dysfunction and degenerative sacroiliitis. The assembly includes a first implant body, a second implant body, and a piezoelectric layer positioned between them. The piezoelectric layer generates electrical charges when subjected to mechanical stress, stimulating bone growth and enhancing stability of the SI joint after surgery. The implant bodies may feature non-planar surfaces to distribute compressive and shear forces unevenly across the piezoelectric layer. The assembly can be secured using fasteners such as screws, pins, or brackets, and may include porous or fenestrated bodies made from materials like titanium or polymers. Some implant assemblies are designed for minimally invasive surgical procedures, with configurations that allow for precise placement using guide wires and imaging techniques. The assembly aims to stabilize the SI joint and promote bone fusion, leveraging the piezoelectric effect to improve the overall efficacy of the fusion procedure.

Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation, and symptoms of menopause.

The present invention provides an aqueous pharmaceutical product comprising an anti-IL-17A antibody, and a use of the aqueous pharmaceutical product in the preparation of a drug for treating axial spondyloarthritis.

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and / or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and / or prophylaxis of diseases, especially for treatment and / or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

A method for modeling temporomandibular joint osteoarthritis, 6-week-old rats are selected, the rats are confirmed to have entered an anesthetized state before surgery, the rat's mandibular incisors are first checked and confirmed to be normal, the first arm of the device is sleeved on one side of the mandibular incisor, and the palatal side of the maxillary incisor is made to touch the slope surface of the second arm of the device, the device is checked and confirmed to not affect the rat's mandibular movement and occlusion, not significantly raise the bite, have no early contact, and the upper and lower jaw relationship is relatively stable; the device and the mandibular incisor sleeved with the device are fixed; then the rat is put back into the cage, and soft food or powdered feed is given after waking up; the device is removed after being fed for 8 weeks or more. It is verified that the condylar process of the rat changes significantly, the overall condylar process is significantly reduced, the subchondral bone is destroyed, and the expression of the cartilage matrix is also reduced. Thus, a TMJOA rat model exhibiting mandibular retrusion is formed.

This disclosure provides substituted 6-imidazopyridazine compounds for the modulation of IL-17A and pharmaceutical compositions thereof. These compounds are useful in the treatment of inflammatory conditions such as psoriasis, psoriatic arthritis, or ankylosing spondylitis.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, utilizing anti-IL-23A antibodies.

This application discloses a medical information data processing system and method for spondyloarthritis based on an intelligent agent learning model. The system includes: a pre-consultation intelligent agent module for generating an initial medical record in response to the patient's pre-consultation interaction data; a medical data processing intelligent agent module for acquiring the initial medical record and the patient's heterogeneous medical test data, and extracting medical entity information data related to spondyloarthritis from the initial medical record and heterogeneous medical test data using a BERT-BiLSTM-CRF hybrid model, and determining the entity information links formed by the medical entity information data using an EMR-Graph entity relationship graph model; and a medical reasoning intelligent agent module for performing reasoning analysis on the entity information links using an LSTM-TPP model to obtain the initial reasoning probability between the patient and spondyloarthritis. This module can fully consider the link relationship between medical entity information related to spondyloarthritis during the disease probability reasoning process, thereby effectively improving the accuracy of disease probability reasoning.

The invention belongs to the technical field of biological medicines, and particularly relates to a drug-loaded nano-micelle as well as a preparation method and application thereof. According to the invention, bromoalkanes with different chain lengths are introduced to a leonurine phenolic hydroxyl group by adopting a total synthesis method to prepare a leonurine derivative, and the drug-loaded nano-micelle is prepared by applying triptolide (TP) and the leonurine derivative. The embodiment of the invention verifies that the drug-loaded nano-micelle can reduce in-vivo and in-vitro toxicity caused by triptolide and improve the treatment effect on a mouse arthritis model induced by type II collagen. The novel triptolide compatible medicine prepared by the invention is small in toxic and side effects and has a good curative effect on rheumatoid arthritis.

The invention provides certain difluorotetrahydropyran-imidazotriazine compounds of formula I as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula I to treat psoriasis, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, hidradenitis suppurativa, systemic lupus erythematosus, palmoplantar pustulosis (PPP), atopic dermatitis, asthma, non-infectious uveitis, or COPD.

The application relates to the technical field of animal models, and discloses a construction method and application of an ectopic ossification arthritis animal model. 91‑115 After being mixed and emulsified with chicken type II collagen as an antigen, animals are immunized to obtain the animal model, which is referred to as a C2V7 model. The arthritis model constructed by the application has high success rate, short time consumption and easily-obtained modeling materials. The model can simulate the onset process of arthritis with obvious ectopic ossification characteristics such as ankylosing spondylitis, enthesial-related arthritis and psoriatic arthritis, objectively reflects the pathological process and pathological characteristics of ectopic ossification arthritis, and provides a new research platform for related research.

The present invention relates to montelukast for use in the treatment of erosive hand osteoarthritis. According to this use, montelukast can be administered either orally or topically, in the form of any suitable pharmaceutical composition. Patients suffering from erosive hand osteoarthritis treated with montelukast showed improvement in clinical symptoms and in radiological parameters, and also reported pain relief and hand functionality improvement.

This application discloses a system and method for processing precise synthetic CT images of the spine based on deep learning algorithms for axial spondyloarthritis. The system includes: a data acquisition unit for acquiring three-dimensional T1-weighted multi-gradient echo sequences, T2-weighted sequences, and water-lipid separation sequences obtained from magnetic resonance imaging of the target user's spine; a spatial registration unit for inputting multi-sequence data into a deformable registration network to perform spatial registration of multimodal features; a feature processing unit for fusing the registered multimodal features and performing dual-domain splitting based on an anatomical attention gating mechanism to obtain skeletal features and soft tissue features; and an image fusion unit for synthesizing synthetic CT images with HU values ​​corresponding to the target user's spine based on skeletal features and soft tissue features, achieving radiation-free, high-precision CT image acquisition, which can meet the diagnostic and grading requirements of axial spondyloarthritis while reducing the impact of radiation on the target user.

The invention provides certain tetrahydropyran-imidazotriazine compounds of formula (I) as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula (I) to treat psoriasis, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, hidradenitis suppurativa, systemic lupus erythematosus, palmoplantar pustulosis (PPP), atopic dermatitis, asthma, non-infectious uveitis, or COPD.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

The invention provides certain imidazotriazine compounds of formula I as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula I or II to treat psoriasis, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, hidradenitis suppurativa, systemic lupus erythematosus, palmoplantar pustulosis (PPP), atopic dermatitis, asthma, non-infectious uveitis, or COPD.

This invention discloses a neutralizing nanobody targeting soluble interleukin-17 receptor D (sIL-17RD), its preparation method, and its applications. The heavy chain variable region (VHH) of this nanobody contains a heavy chain complementarity-determining region 3 (CDR-H3) that specifically binds to sIL-17RD, with a length of 10 amino acids and containing 2–6 lysine residues. This invention provides four nanobodies: CQ5, CQ13, CQ11, and CQ6, corresponding to well-defined CDR-H1, CDR-H2, and CDR-H3 sequence combinations. This nanobody can specifically bind to and neutralize the biological activity of sIL-17RD, reducing chondrocyte death, promoting proliferation, and maintaining extracellular matrix homeostasis by inhibiting the P2rx7-NLRP3 inflammasome-mediated chondrocyte pyroptosis pathway. This invention also protects the nucleic acid encoding this nanobody, the recombinant expression vector, the host cell, the pharmaceutical composition, and the preparation method. The nanobodies described can be used to prepare drugs for the prevention and treatment of inflammatory osteoarthritis and other osteoarthritis. They can inhibit synovitis, reverse cartilage and subchondral bone degeneration, and relieve pain, showing promising application prospects.

The present invention relates to methods of treating inflammatory diseases, including methods of treating IL-23 related diseases, in particular inflammatory diseases such as psoriasis, psoriatic arthritis or central axis (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and radionegative ax-SpA, using an anti-IL-23A antibody.

The present disclosure relates to an ultrasound guided intraarticular administration of a combination of a composition comprising pooled mesenchymal stromal cells, and mid molecular weight hyaluronic acid for treatment of osteoarthritis. The disclosure also provides methods for increasing levels of anti-inflammatory marker and decreasing levels of disease progression marker in a human subject suffering from osteoarthritis through the use of the said combination. The present disclosure accordingly also relates to a kit comprising the said composition and the hyaluronic acid as such for the said use and treatment.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

The present invention in general relates to the field of antibody profiling in spondyloarthritis. In particular, the inventors found that antibody levels against selected peptides are raised in spondylarthritis patients, and herein provide a diagnostic method and kit comprising such peptides for use in the diagnosis of spondyloarthritis.

The present invention relates to methods of treating inflammatory diseases, including methods of treating IL-23 associated diseases, in particular inflammatory diseases such as psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and radiographic negative ax-SpA, using anti-IL-23A antibodies.

Apparatus and methods are described including obtaining from a subject at least a first and second blood product sample. A first infrared spectrum of the first blood product sample is obtained by performing a first infrared spectroscopy measurement, and a second infrared spectrum of the second blood product sample is obtained by performing a second infrared spectroscopy measurement. A computer processor analyzes the first and second infrared spectra, and at least partially in response thereto, determines a status of the subject with respect to fibromyalgia syndrome, rheumatoid arthritis, psoriatic arthritis, and / or ankylosing spondylitis. Other applications are also described.

The disclosure relates to novel regimens for treating an inflammatory arthiritis. e.g., psoriatic arthritis. which employ a therapeutically effective amount of an Interleukin- 17 (IL-17) antagonist. e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof. e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).

The application discloses a kind of middle axis type spondyloarthritis sacroiliac joint MRI synthetic CT image processing system and method based on deep learning algorithm, system includes: data acquisition unit, for obtaining the magnetic resonance sequence data obtained by magnetic resonance imaging to target user sacroiliac joint;Deep learning model unit, for the magnetic resonance sequence data is input to the deep learning algorithm model trained using federation learning, obtain the bone cortex feature and soft tissue feature of sacroiliac joint;Image synthesis unit, for synthesizing the synthetic CT image corresponding to the sacroiliac joint of the target user based on the bone cortex feature and the soft tissue feature, realize the high-precision CT image acquisition of no radiation, both can satisfy the diagnosis demand to middle axis type spondyloarthritis sacroiliac joint, and can reduce the influence of radiation to target user.

The invention provides certain tetrahydropyran-imidazotriazine compounds of formula I or II as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula I or II to treat psoriasis, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, hidradenitis suppurativa, systemic lupus erythematosus, palmoplantar pustulosis (PPP), atopic dermatitis, asthma, non-infectious uveitis, or COPD.

Provided is a liquid preparation containing an anti-IL-17 antibody at a concentration of 20 mg / mL to 200 mg / mL, a citrate buffer at a concentration of 10 mM to 50 mM, a sucrose at a concentration of 20 mg / mL to 120 mg / mL or arginine at a concentration of 50 mM to 250 mM, and polysorbate 80 at a concentration of 0.1 mg / mL to 5 mg / mL. In addition, the liquid preparation has a pH of 6.0±0.5, wherein the anti-IL-17 antibody is an anti-IL-17A / F monoclonal antibody. The liquid preparation can be a stable subcutaneous injection preparation, and can be used to treat IL-17A and / or IL-17F related diseases, such as psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, osteoarthritis or inflammatory bowel disease.

The embodiments of the present disclosure provide a composition including mitochondria. By providing the mitochondria to cartilage, the composition can improve the mitochondrial function of the chondrocytes in the cartilage so as to increase the repair ability of the chondrocytes and repair the cartilage damage caused by aging of the chondrocytes, thereby achieving the purpose of treating osteoarthritis.